News | June 18, 2020

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies...